NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Last updated: May 11, 2023
Sponsor: Centre Hospitalier Saint Joseph Saint Luc de Lyon
Overall Status: Active - Recruiting

Phase

N/A

Condition

Joint Injuries

Collagen Vascular Diseases

Arthritis And Arthritic Pain (Pediatric)

Treatment

N/A

Clinical Study ID

NCT05744297
ActiNG
  • Ages > 18
  • All Genders

Study Summary

Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven by NLRP3 inflammasome and IL1-beta production.

However pathogenesis of acute gout flares remains poorly known in vivo in human.

The aim of this study is to evaluate NLRP3 inflammasome activation in vivo in patients cells during acute gout flares.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Hospitalization for acute gout flare confirmed by joint fluid analysis or Nijmegenscore > 8
  • Aged > 18

Exclusion

Exclusion Criteria:

  • Gout treatment already started
  • Inflammatory Arthritis other than Gout Arthritis
  • Pregnant or breast feeding women
  • Patient protected by law

Study Design

Total Participants: 10
Study Start date:
April 28, 2023
Estimated Completion Date:
October 31, 2023

Study Description

Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.

Connect with a study center

  • Centre Hospitalier Saint Joseph Saint Luc

    Lyon, 69007
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.